NASDAQ:CUE

Cue Biopharma Stock Forecast, Price & News

$12.84
-0.11 (-0.85 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$12.60
Now: $12.84
$13.28
50-Day Range
$11.20
MA: $13.11
$15.85
52-Week Range
$10.75
Now: $12.84
$31.69
Volume247,797 shs
Average Volume312,260 shs
Market Capitalization$391.07 million
P/E RatioN/A
Dividend YieldN/A
Beta1.95
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded by Ronald D. Seidel III, Steven Almo, and, Rodolfo Chaparro on December 31, 2014 and is headquartered in Cambridge, MA.
Cue Biopharma logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CUE
CUSIPN/A
Phone(617) 949-2680
Employees45
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.46 million
Book Value$2.37 per share

Profitability

Net Income$-36,700,000.00
Net Margins-1,142.70%

Miscellaneous

Market Cap$391.07 million
Next Earnings Date5/6/2021 (Estimated)
OptionableNot Optionable

Headlines

Cue Biopharma earnings preview: what Wall Street is expecting
March 14, 2021 |  markets.businessinsider.com
Cue Biopharma to Present at the 7th Annual Immuno-Oncology 360° Conference
February 23, 2021 |  markets.businessinsider.com
7 Stocks With Insider Buying This Week Worth A Look
February 6, 2021 |  finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

1.33 out of 5 stars

Medical Sector

761st out of 2,024 stocks

Pharmaceutical Preparations Industry

364th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 1.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
$12.84
-0.11 (-0.85 %)
(As of 04/16/2021 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CUE News and Ratings via Email

Sign-up to receive the latest news and ratings for CUE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cue Biopharma (NASDAQ:CUE) Frequently Asked Questions

Is Cue Biopharma a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cue Biopharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Cue Biopharma stock.
View analyst ratings for Cue Biopharma
or view top-rated stocks.

What stocks does MarketBeat like better than Cue Biopharma?

Wall Street analysts have given Cue Biopharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cue Biopharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Cue Biopharma's next earnings date?

Cue Biopharma is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Cue Biopharma
.

How were Cue Biopharma's earnings last quarter?

Cue Biopharma, Inc. (NASDAQ:CUE) issued its quarterly earnings results on Tuesday, March, 16th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.35) by $0.02. Cue Biopharma had a negative trailing twelve-month return on equity of 63.69% and a negative net margin of 1,142.70%.
View Cue Biopharma's earnings history
.

How has Cue Biopharma's stock price been impacted by Coronavirus (COVID-19)?

Cue Biopharma's stock was trading at $15.71 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CUE stock has decreased by 18.3% and is now trading at $12.84.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for CUE?

4 Wall Street analysts have issued twelve-month target prices for Cue Biopharma's stock. Their forecasts range from $30.00 to $33.00. On average, they expect Cue Biopharma's share price to reach $31.25 in the next year. This suggests a possible upside of 143.4% from the stock's current price.
View analysts' price targets for Cue Biopharma
or view top-rated stocks among Wall Street analysts.

Who are Cue Biopharma's key executives?

Cue Biopharma's management team includes the following people:
  • Daniel R. Passeri, Chief Executive Officer & Director
  • Anish Suri, President & Chief Scientific Officer
  • Kerri-Ann Millar, Chief Financial & Accounting Officer
  • Ronald D. Seidel, EVP, Head-Research & Development
  • Kenneth J. Pienta, Chief Medical Officer

Who are some of Cue Biopharma's key competitors?

What other stocks do shareholders of Cue Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cue Biopharma investors own include Provention Bio (PRVB), NVIDIA (NVDA), OPKO Health (OPK), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), AT&T (T) and Advanced Micro Devices (AMD).

What is Cue Biopharma's stock symbol?

Cue Biopharma trades on the NASDAQ under the ticker symbol "CUE."

Who are Cue Biopharma's major shareholders?

Cue Biopharma's stock is owned by a number of retail and institutional investors. Top institutional investors include Sanders Morris Harris LLC (1.15%). Company insiders that own Cue Biopharma stock include Aaron GL Fletcher, Anish Suri, Cameron Gray, Christopher A Marlett, Colin Sandercock, Daniel R Passeri and Kenneth Pienta.
View institutional ownership trends for Cue Biopharma
.

Which major investors are buying Cue Biopharma stock?

CUE stock was acquired by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC. Company insiders that have bought Cue Biopharma stock in the last two years include Aaron GL Fletcher, Cameron Gray, Colin Sandercock, Daniel R Passeri, and Kenneth Pienta.
View insider buying and selling activity for Cue Biopharma
or or view top insider-buying stocks.

How do I buy shares of Cue Biopharma?

Shares of CUE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cue Biopharma's stock price today?

One share of CUE stock can currently be purchased for approximately $12.84.

How much money does Cue Biopharma make?

Cue Biopharma has a market capitalization of $391.07 million and generates $3.46 million in revenue each year. The company earns $-36,700,000.00 in net income (profit) each year or ($1.66) on an earnings per share basis.

How many employees does Cue Biopharma have?

Cue Biopharma employs 45 workers across the globe.

What is Cue Biopharma's official website?

The official website for Cue Biopharma is www.cuebiopharma.com.

Where are Cue Biopharma's headquarters?

Cue Biopharma is headquartered at 21 ERIE STREET, CAMBRIDGE MA, 02139.

How can I contact Cue Biopharma?

Cue Biopharma's mailing address is 21 ERIE STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at (617) 949-2680 or via email at [email protected]


This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.